Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.

@article{Ferdinandi2007NonclinicalPA,
  title={Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.},
  author={E. Ferdinandi and P. Brazeau and K. High and B. Procter and S. Fennell and P. Dubreuil},
  journal={Basic & clinical pharmacology & toxicology},
  year={2007},
  volume={100 1},
  pages={
          49-58
        }
}
TH9507, an analogue of human growth hormone-releasing factor (hGRF1-44NH2) minimally modified by addition of a trans-3-hexenoyl moiety to Tyr1 of the amino acid sequence, was found to be resistant to dipeptidyl aminopeptidase-IV deactivation. Compared to natural hGRF1-44NH2, the modification slowed the in vitro degradation of the peptide in rat, dog and human plasma and prolonged the in vivo plasma elimination kinetics of immunoreactive TH9507. Plasma growth hormone and insulin-like growth… Expand
21 Citations
Tesamorelin, a human growth hormone releasing factor analogue
  • 4
Spotlight on Tesamorelin in HIV-Associated Lipodystrophy
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
  • 13
  • Highly Influenced
Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides
  • 113
Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS
  • 14
Strategic Approaches to Optimizing Peptide ADME Properties
  • L. Di
  • Chemistry, Medicine
  • The AAPS Journal
  • 2014
  • 209
...
1
2
3
...

References

SHOWING 1-10 OF 32 REFERENCES
Biosynthetic human growth hormone: subchronic toxicity studies in rats and monkeys.
  • 29
Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted at position-1.
  • 42
...
1
2
3
4
...